Natural Resources for Human Health

eISSN: 2583-1194

Original Research

Received 12 Oct 2024
Revised 18 Nov 2024
Accepted 25 Dec 2024

Natural Resources for Human Health 2024, Vol. 4 (1s): 212–218

KEYWORDS:
"Nanotechnology, targeted, drug delivery, challenges, recent, advancement, future, perspectives

Nanotechnology-Based Targeted Drug Delivery Systems: Recent Advances, Key Challenges, and Future Perspectives

Mona Awad Alanazi[1], Renad Hilal Khulaif Aljabri[2], Yousef Abdullah Saad Alarifi[3], Hasan Ali Hasan Aljaizani[3], Sultan Ibrahim Ahmed Amannaa[3], Abdullah Saud Nahar Alotaibi[4], Lujain Khalid Khan[5], Nouf Hasan Alahmadi[6], Yara Khaled Qorban[7], Ahmed Othman Abdallh ALmehdawi[8], Talal Quayyid Hubaylis Al Otaibi[9], Khalid Ewisi H Alshammari[10], Abdalelah Mohammed Abdulrahman Alfhad[11]

[1]Pharmacist, Prince mohammed bin abdulaziz hospital, Saudi Arabia.
[2]Pharmacist, Al salam Endowment Hospital, Saudi Arabia.
[3]Pharmacist Assistant, king saud medical city, Saudi Arabia.
[4]Pharmacist Technician, Al-Dawadmi General Hospital, Saudi Arabia.
[5]Drug information supervisor, Maternity and children hospital, Saudi Arabia.
[6]Pharmacist, Central medication officer King Abdulaziz Hospital, Saudi Arabia.
[7]Medication safety officer, King abdulaziz hospital, Saudi Arabia.
[8]Pharmacy Technician, Al Laith General Hospital, Saudi Arabia.
[9]Pharmacy Assistant, Al-Quway'iyah General Hospital, Saudi Arabia.
[10]Technician pharmacy, Licensing Department – Ministry of Health Branch in Riyadh, Saudi Arabia.
[11]Pharmacy Technician, Shaqra General Hospital, Saudi Arabia.

ABSTRACT: Background: A notable increase in cancer-related fatalities and morbidity worldwide is attributed to drug resistance. The factors contributing to drug resistance include drug efflux via ABC transporters, apoptosis evasion, epigenetic alterations, DNA repair mechanisms, and the tumor microenvironment, among others. Systemic toxicities and resistance associated with conventional cancer diagnostics and therapies have led to the development of alternative approaches, such as nanotechnology, to enhance diagnostic precision and improve therapeutic outcomes. Globally, breast cancer remains a leading cause of cancer-related mortality among women, emphasizing the need for more effective therapies. Nanotechnology-based drug delivery systems have emerged as promising tools for reducing systemic toxicity while enhancing the precision and efficacy of treatments. By engineering nanoparticles to selectively target tumor cells, these systems increase drug accumulation at the tumor site and minimize harm to healthy tissues. Nanoparticles for the targeted delivery of chemotherapeutic agents in breast cancer.

Aim: To bring attention to the promising future of Nan medicine by show casing its potential applications in areas such as sustainable and individualized healthcare. Rustle he future of nanotechnology in drug delivery is poised for transformative growth, with the integration of AI, the development of sustainable nanomaterial's, and the advent of multifunctional theranostic Nan carriers. These innovations promise to not only enhance the precision and effectiveness of treatments but also address key challenges such as environmental sustainability, personalized healthcare, and real-time monitoring of therapeutic outcomes. Despite significant progress, challenges such as regulatory hurdles,

tumor heterogeneity, multidrug resistance, issues related to nanoparticle biocompatibility continue to impede clinical translation.

Conclusion: In conclusion, the complex challenge of drug resistance in cancer therapy presents a formidable hurdle that significantly diminishes the efficacy of conventional treatments. This resistance primarily arises from various mechanisms, including drug efflux, genetic mutations, epigenetic modifications, and the intricate tumor microenvironment (TME). The advent of nanotechnology undoubtedly offers a powerful promise in addressing these obstacles. The barriers posed by drug resistance can be mitigated through targeted drug delivery specificity and reduced systemic toxicity.

INTRODUCTION

Nanotechnology in drug delivery has revolutionized modern therapeutics by addressing the limitations of conventional drug delivery methods. This review article explores the significant advancements in nanoparticle-based drug delivery systems, highlighting their role in enhancing therapeutic efficacy and overcoming drug resistance. (1) Nanoparticles, including lipid-based, polymer-based, inorganic, and biological types, offer improved solubility, stability, targeted delivery, and controlled release of therapeutic agents. By enabling precise delivery to specific tissues or cells, these advancements minimize off-target effects and toxicity, particularly in cancer therapy. Additionally, Nan medicine facilitates the delivery of drugs across biological barriers such as the blood-brain barrier, which opens new avenues for treating neurological disorders. (2) The ability to co-encapsulate multiple therapeutic agents in nanoparticles also supports combination therapies that target multiple pathways simultaneously, thereby reducing the development of resistance. As research progresses, the integration of nanotechnology in drug delivery promises to transform healthcare by providing more effective, safer, and personalized treatments. This article supports continued exploration and innovation in the field by emphasizing the need for interdisciplinary collaboration to fully realize the potential of Nan medicine in improving patient outcomes and addressing unmet clinical needs.

Cancer therapies often compromised due to the significant challenge of drug resistance. This resistance arises from multiple factors, including drug deactivation, changes in drug targets, evasion of apoptosis, drug efflux, DNA damage repair, cell heterogeneity, and immune system escape within the tumor microenvironment (TME) (3). Several transporters, expressed in various tissues, contribute to drug resistance by trans locating numerous substances, including drugs, across the plasma membrane (4). Genetic instability is another major factor that leads to reduced cell differentiation and maturation, with poor contact inhibition resulting in the transition from benign to aggressive malignancies (5). Moreover, alterations in the lipid composition and synthesis of the plasma membrane play a critical role in the development of drug resistance phenotypes. These changes hinder intracellular drug transportation and reduce the cytotoxic effects of chemotherapy (6). The complexity of these resistance mechanisms underscores the necessity for targeted therapies to manage drug resistance in cancer treatment (7)

The use of nanotechnology has greatly improved medication delivery, especially in removing biological obstacles to treatment. Nanoparticles, which can be anywhere from 1 to 100 nanometers in size, have the potential to revolutionize therapeutic interventions by increasing their solubility, bioavailability, and stability while allowing for controlled and targeted release. The BBB, the tumor microenvironment, and immune system responses are some of the biological obstacles that pose a significant threat to drug delivery. By manipulating their size and shape, nanoparticles can bypass these obstacles and transport medications to the sites of injury with little risk to the central nervous system. For instance, by leveraging specialized surface features like lipophilicity or receptor-mediated endocytosis, nanocarriers developed for brain-targeting applications can traverse the blood-brain barrier (BBB), which is ordinarily impervious to most medications.(8)

Additionally, nanoparticles make tumor-targeted therapy possible through the Enhanced Permeability and Retention (EPR) effect, which allows nanoparticles to selectively aggregate in tumor tissue due to characteristics of the tumor vasculature (such as leaky blood vessels). Nanoparticles can reduce side effects by making better use of this method to deliver chemotherapeutic drugs to cancer cells with less damage to healthy tissues. In addition, theranostics allows for ongoing tracking of medication distribution and therapeutic results using a single nanocarrier, allowing for adaptive treatment modifications in response to diagnostic data (9)

A growing number of diseases, including cancer, neurological disorders, infectious diseases, autoimmune disorders, and cardiovascular diseases, are finding ways to overcome biological barriers with the help of nanotechnology. Patients are more

likely to take their medications as prescribed and experience better outcomes from their therapies when nanoparticles are tailored to increase drug solubility, target certain receptors or antigens, and provide controlled or sustained release of therapeutic substances.(10)

Nanotechnology shows a lot of potential for the future of medication administration. The effectiveness of treatments and the reduction of dangers can be further improved with the development of increasingly complex nanoparticles that integrate targeted delivery, controlled release, and diagnostic capabilities. Optimizing these systems for personalized medicine, which offers tailored medicines that fit the needs of patients, will also rely on the integration of nanotechnology, biomaterials, and artificial intelligence. Before nanomedicine can reach its full potential in everyday clinical practice, however, issues with production scalability, regulatory clearance, and long-term safety need to be resolved.(11)

A game-changer in the field of pharmaceutical sciences, nanotechnology for targeted drug delivery is altering the way drugs are given and absorbed by the body . Drugs can be administered directly to specific cells or tissues using nanoscale carriers as dendrimers, polymeric nanoparticles, or liposomes. This improves efficacy and minimizes negative effects. Methods such as active targeting, in which ligands direct nanoparticles to certain receptors, and passive targeting, which takes advantage of the increased permeability of sick tissues, allow for such precision. (12)

This technology has the potential to improve results while reducing systemic problems in a variety of important fields, such as cancer treatment, neurological disorders, and infectious diseases. Production costs, possible toxicity, and regulatory difficulties are some of the challenges that need to be solved, despite its promise. Innovative solutions for complicated medical problems are emerging from the convergence of diagnosis and therapy made possible by nanotechnology, which is rapidly shaping the future of personalized medicine.(13)

Nanotechnology in Medicine

Structures, devices, and systems on the nanoscale scale (1-100 nanometers) are the focus of nanotechnology, a subfield of engineering and science. When compared to their larger-scale equivalents, materials at this size have distinct physical, chemical, and biological characteristics. Because of these characteristics, nanotechnology has a lot of potential in many fields, including medicine. By paving the way for advancements in regenerative medicine, drug delivery, and diagnostics, nanotechnology is revolutionizing the healthcare industry. Nanocarriers, including liposomes and nanoparticles, have several uses, one of the most important of which is targeted drug delivery, which involves delivering medications just to sick tissues while avoiding healthy ones. (14)

Furthermore, imaging agents and nan sensors are examples of highly sensitive diagnostic tools that make use of nanotechnology to enable earlier and more precise illness identification. Wound healing, bioengineered tissues, and vaccine research (using lipid nanoparticle technology, for example, in mRNA vaccines) are some other potential uses for nanomaterials. The field of modern medicine being transformed by nanotechnology, which takes advantage of the distinct characteristics of nanomaterial's . (15)

Historical overview of its integration into drug delivery systems.

Innovations in biomedical engineering and materials science have spurred substantial progress in the last several decades toward fully integrating nanotechnology into medication delivery systems. The initial major stride toward drug delivery by nanoparticles occurred in the 1960s, when the concept of drug-encapsulating vesicles called liposomes was initially proposed. Later on, liposomes' capacity to increase the solubility and stability of drugs led to their use in cancer treatment and other medical domains.(16)

Polymeric nanoparticles, dendrimers, and metallic nanoparticles were developed during the 1990s and early 2000s, causing a surge in nanotechnology. Thanks to these advancements, medication release could be better managed, targeting could be enhanced, and systemic toxicity could be decreased. Passive targeting, which involves guiding nanoparticles to tumor tissues via the Enhanced Permeability and Retention (EPR) effect, first appeared at this time. (17) To bind exclusively to sick cells, researchers in the 2010s investigated active targeting strategies that involved attaching ligands, antibodies, or peptides to nanocarriers. At the same time, the clinical potential of nanotechnology was brought to light by the approval of Nan medicines such as Doxil® (liposomal doxorubicin) and Abraxane® (albumin-bound paclitaxel). (18)

Drug delivery tactics have been further optimized in recent years due to advancements in stimuli-responsive systems, smart nan carriers, and theranostics, which combines therapy and diagnostics. Lipid nanoparticles' efficacy in COVID-19 mRNA

vaccines has established nanotechnology as a cornerstone of contemporary medicine, opening the door to its expanded use in precision and individualized healthcare. (19)

Types of Nanocarriers for Drug Delivery

Phospholipid bilayers encase an aqueous core in liposomes, which are spherical vesicles. These structures are biocompatible and have medicinal potential since they resemble real biological membranes. Since their description in the 1960s, liposomes have risen to prominence as a leading nanocarrier for drug delivery, receiving much research and practical application. Because of their unusual structure, they can encapsulate medications with both hydrophilic and hydrophobic properties. Transporting a diverse variety of therapeutic medicines is made possible by the ability to house water-soluble pharmaceuticals in the aqueous core and hydrophobic drugs in the lipid bilayer. Liposomes are highly advantageous for medications that are not very water-soluble since they encapsulate the molecule, make it more stable, and increase its solubility.(20)

The capacity to tailor liposomes for specific medication delivery is a major benefit. To improve therapeutic efficacy and decrease off-target effects, ligands like antibodies, peptides, or sugars can be attached to the surface of liposomes, allowing them to be directed to certain cells or tissues. Another advantage of liposome engineering is the ability to have them respond to changes in environmental factors such as pH or temperature by releasing their contents. Liposomal formulations like Ambisome® (liposomal amphotericin B) and Doxil® (liposomal doxorubicin) have shown efficacy in treating fungal infections and cancer, respectively, in clinical trials. The importance of liposomes in the advancement of medication delivery systems based on nanotechnology has been brought to light by these advances.(21)

Nano emulsions and Micelles: Enhanced solubility for poorly soluble drugs

The size of the oil phase, the water phase, and the surfactants in a nan emulsion usually vary between 20 and 200 nanometers, making it a sort of colloidal dispersion. To improve the absorption and effectiveness of hydrophobic (lipophilic) medications, these emulsions aid to solubilize them. They are stable systems from a thermodynamic perspective. Nan oemulsions can encapsulate pharmaceuticals with different solubility properties, allowing for improved bioavailability of substances that are not particularly soluble. Nan emulsions allow for precise dosing control by adjusting the surfactant composition and characteristics. Oral, parenteral, and topical drug delivery methods all make use of nan oemulsions, and they're especially useful for meds that need to be absorbed more quickly or released over a longer period. They are also used for hormones, vitamin, and antioxidant administration.(22)

When surfactants are dissolved in water, they self-assemble into micelles, which are amphiphilic nanostructures with hydrophilic and hydrophobic components. The core-shell configuration of surfactant molecules is formed by the hydrophobic "tails" clustering inward and the hydrophilic "heads" facing outward. Micelles usually have a size between ten and one hundred nanometers. Micelles are a great way to improve the solubility of lipophilic medications that aren't very water-soluble. This makes them easier to disperse and absorb in watery settings, such as the GI tract. (23)

Benefits of Nanotechnology in Drug Delivery

When it comes to drug distribution, nanotechnology has a lot of great advantages that can make treatments safer and more effective. The improved solubility and bioavailability of medications, especially those with low water solubility, is a major benefit. Encapsulating hydrophobic medications in nanocarriers like micelles, nanoparticles, or liposomes makes them more soluble in water, which improves their absorption in the body. Because nanocarriers can help achieve therapeutic concentrations with smaller doses, greatly decreasing the requirement for high drug amounts and boosting the overall effectiveness of the treatment, this is especially helpful for drugs with low bioavailability.(24)

Another significant advantage of medicine delivery based on nanotechnology is improved patient compliance. Patients may not adhere to treatment regimens when they are required to take many medications at once, which can be a nuisance. The medicine can be released gradually over a long period of time using nanocarriers that have been developed for controlled release. This makes it easier for the patient to take their medication as directed, which in turn increases the likelihood that they will adhere to their treatment plans. Chronic diseases require long-term care, therefore the ability to establish stable therapeutic levels without frequent administration is very useful.(25)

Nanotechnology is a potent tool in contemporary pharmacological treatment because it increases bioavailability, decreases toxicity, and improves patient compliance with medication delivery. Nanotechnology has many potential uses, but there are

also certain restrictions and difficulties associated with using it to deliver drugs. The high expense of development and production is one of the primary hurdles. Complex and costly procedures are frequently involved in the synthesis, formulation, and scaling-up of nanocarriers such as liposomes, nanoparticles, and others. Raw material costs, the price of necessary technology and equipment, and the time and effort put into labor-intensive production processes to guarantee quality and consistency all factor into this. Therefore, nanotechnology-based drug delivery systems may not be widely used, especially in settings with limited resources, due to their potentially much higher production costs compared to standard drug delivery methods. (26)

Developing and approving drug delivery systems based on nanotechnology is complex, as there are currently no standardized testing methodologies and several regulatory impediments. There are currently no widely agreed-upon standards for assessing the quality, safety, and effectiveness of nanoparticles utilized in medication delivery, and regulatory bodies like the FDA and EMA are still adjusting to the novel aspects of nanomedicine. Each nanoparticle formulation may have to go through unique, thorough testing for toxicity, pharmacokinetics, and effectiveness prior to being approved for clinical use, which makes the approval process more complicated due to the lack of common testing methodologies. The development of pharmaceuticals based on nanotechnology can be costly and time-consuming due to the various regulatory hurdles that must be overcome.(27)

Nanotechnology has enormous promise for medication delivery, but there are still many obstacles to overcome before it can reach its full potential in clinical practice, including its high cost, possible toxicity issues, and regulatory and safety hurdles.

Another key area of development is the advancement of biodegradable and eco-friendly nanomaterials. As concerns about the environmental impact of nanomaterials grow, there is increasing focus on developing nanoparticles that are not only safe for human use but also environmentally sustainable. Biodegradable polymers and naturally derived materials are being explored to replace synthetic and potentially harmful substances. These materials can degrade safely in the body or environment, reducing long-term toxicity and environmental accumulation, which is particularly important as nanomedicines become more widely used in clinical practice. (28)

Furthermore, the development of multifunctional nanocarriers is opening new possibilities for theranostics, a combined approach of therapy and diagnosis. These nanocarriers are engineered to carry both therapeutic agents (such as drugs or genetic material) and diagnostic tools (such as imaging agents or sensors) in a single nanoparticle. This dual functionality allows for the real-time monitoring of therapeutic responses and the ability to adjust treatment strategies dynamically. For example, nanoparticles could be used to deliver chemotherapy while simultaneously enabling imaging to track drug delivery and assess treatment effectiveness. Such theranostic nanocarriers have the potential to improve treatment outcomes, reduce the need for separate diagnostic procedures, and allow for more personalized and timely interventions. (29)

The future of nanotechnology in drug delivery is poised for transformative growth, with the integration of AI, the development of sustainable nanomaterials, and the advent of multifunctional **theranostic** nan ocarriers. These innovations promise to not only enhance the precision and effectiveness of treatments but also address key challenges such as environmental sustainability, personalized healthcare, and real-time monitoring of therapeutic outcomes.(30)

CONCLUSION

Nanotechnology holds immense potential to revolutionize drug delivery, offering more efficient, precise, and targeted treatments for a wide range of diseases. The advancements in nanocarriers, such as liposomes, dendrimers, and metallic nanoparticles, have significantly improved drug solubility, bioavailability, and therapeutic efficacy, while minimizing side effects and toxicity. However, challenges such as high development costs, potential long-term safety concerns, and regulatory hurdles remain, requiring continued research and innovation. The future of nanomedicine looks promising, with emerging trends like the integration of AI for personalized treatment, the development of biodegradable and eco-friendly nanomaterials, and the creation of multifunctional theranostic systems that combine therapy and diagnosis. As these technologies evolve, they hold the potential to transform healthcare, providing more effective, sustainable, and tailored therapies that could benefit patients worldwide.

REFERENCES

[1] Malik S, Muhammad K, Waheed Y. Nanotechnology: A Revolution in Modern Industry. Molecules. 2023 Jan 9;28(2):661. doi: 10.3390/molecules28020661. PMID: 36677717; PMCID: PMC9865684.

[2] Malik S, Muhammad K, Waheed Y. Emerging Applications of Nanotechnology in Healthcare and Medicine. Molecules. 2023 Sep 14;28(18):6624. doi: 10.3390/molecules28186624. PMID: 37764400; PMCID: PMC10536529.

[3] Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S, Habtemariam S, Shin HS. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018 Sep 19;16(1):71. doi: 10.1186/s12951-018-0392-8. PMID: 30231877; PMCID: PMC6145203.

[4] Rema Sreenivasan Soumya, Kozhiparambil Gopalan Raghu, Recent advances on nanoparticle-based therapies for cardiovascular diseases, Journal of Cardiology,

[5] Volume 81, Issue 1, 2023, Pages 10-18, ISSN 0914-5087, https://doi.org/10.1016/j.jjcc.2022.02.009.

[6] Rahim MA, Jan N, Khan S, Shah H, Madni A, Khan A, Jabar A, Khan S, Elhissi A, Hussain Z, Aziz HC, Sohail M, Khan M, Thu HE. Recent Advancements in Stimuli Responsive Drug Delivery Platforms for Active and Passive Cancer Targeting. Cancers (Basel). 2021 Feb 7;13(4):670. doi: 10.3390/cancers13040670. PMID: 33562376; PMCID: PMC7914759.

[7] Guimarães D, Cavaco-Paulo A, Nogueira E. Design of liposomes as drug delivery system for therapeutic applications. Int J Pharm. 2021 May 15;601:120571. doi: 10.1016/j.ijpharm.2021.120571. Epub 2021 Apr 2. PMID: 33812967.

[8] Seidu TA, Kutoka PT, Asante DO, Farooq MA, Alolga RN, Bo W. Functionalization of Nanoparticulate Drug Delivery Systems and Its Influence in Cancer Therapy. Pharmaceutics. 2022 May 23;14(5):1113. doi: 10.3390/pharmaceutics14051113. PMID: 35631699; PMCID: PMC9145684.

[9] Preeti, Sambhakar S, Malik R, Bhatia S, Al Harrasi A, Rani C, Saharan R, Kumar S, Geeta, Sehrawat R. Nanoemulsion: An Emerging Novel Technology for Improving the Bioavailability of Drugs. Scientifica (Cairo). 2023 Oct 28;2023:6640103. doi: 10.1155/2023/6640103. PMID: 37928749; PMCID: PMC10625491.

[10] Pinho Melo, Eduardo & Aires-Barros, Maria & Cabral, Joaquim. (2001). Reverse micelles and protein biotechnology. Biotechnology annual review. 7. 87-129. 10.1016/S1387-2656(01)07034-X.

[11] Negut I, Bita B. Polymeric Micellar Systems-A Special Emphasis on "Smart" Drug Delivery. Pharmaceutics. 2023 Mar 17;15(3):976. doi: 10.3390/pharmaceutics15030976. PMID: 36986837; PMCID: PMC10056703.

[12] Zhuo, Y., Zhao, Y. -G., & Zhang, Y. (2024). Enhancing Drug Solubility, Bioavailability, and Targeted Therapeutic Applications through Magnetic Nanoparticles. Molecules, 29(20), 4854. https://doi.org/10.3390/molecules29204854

[13] Chou-Yi Hsu, Ahmed Mahdi Rheima, Mustafa M. Kadhim, Nada Nadhim Ahmed, Srwa Hashim Mohammed, Fatima Hashim Abbas, Zainab Talib Abed, Zahra Muhammed Mahdi, Zainab Sabri Abbas, Safa K. Hachim, Farah K. Ali, Zaid H Mahmoud, Ehsan Kianfar, An overview of nanoparticles in drug delivery: Properties and applications, South African Journal of Chemical Engineering, Volume 46, 2023, Pages 233-270, ISSN 1026-9185, https://doi.org/10.1016/j.sajce.2023.08.009.

[14] Prajapati, A., Rangra, S., Patil, R., Desai, N., Jyothi, V. G. S. S., Salave, S., Amate, P., Benival, D., & Kommineni, N. (2024). Receptor-Targeted Nanomedicine for Cancer Therapy. Receptors, 3(3), 323-361. https://doi.org/10.3390/receptors3030016

[15] A.L.B. Seynhaeve, M. Amin, D. Haemmerich, G.C. van Rhoon, T.L.M. ten Hagen, Hyperthermia and smart drug delivery systems for solid tumor therapy, Advanced Drug Delivery Reviews, Volumes 163–164, 2020, Pages 125-144

[16] ISSN 0169-409X, https://doi.org/10.1016/j.addr.2020.02.004.

[17] Cheng X, Xie Q, Sun Y. Advances in nanomaterial-based targeted drug delivery systems. Front Bioeng Biotechnol. 2023 Apr 13;11:1177151. doi: 10.3389/fbioe.2023.1177151. PMID: 37122851; PMCID: PMC10133513

[18] Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): A current overview of active targeting in brain diseases, Colloids and Surfaces B: Biointerfaces, Volume 221, 2023, 112999, ISSN 0927-7765,https://doi.org/10.1016/j.colsurfb.2022.112999.

[19] Hetta HF, Ramadan YN, Al-Harbi AI, A Ahmed E, Battah B, Abd Ellah NH, Zanetti S, Donadu MG. Nanotechnology as a Promising Approach to Combat Multidrug Resistant Bacteria: A Comprehensive Review and Future Perspectives. Biomedicines. 2023 Jan 31;11(2):413. doi: 10.3390/biomedicines11020413. PMID: 36830949; PMCID: PMC9953167.

[20] Dubey AK, Mostafavi E. Biomaterials-mediated CRISPR/Cas9 delivery: recent challenges and opportunities in gene therapy. Front Chem. 2023 Sep 28;11:1259435. doi: 10.3389/fchem.2023.1259435. PMID: 37841202; PMCID: PMC10568484.

[21] Tobechukwu Christian Ezike, Ugochukwu Solomon Okpala, Ufedo Lovet Onoja, Chinenye Princess Nwike, Emmanuel Chimeh Ezeako, Osinachi Juliet Okpara, Charles Chinkwere Okoroafor, Shadrach Chinecherem Eze, Onyinyechi Loveth Kalu, Evaristus Chinonso Odoh, Ugochukwu Gideon Nwadike, John Onyebuchi Ogbodo, Bravo Udochukwu Umeh, Emmanuel Chekwube Ossai, Bennett Chima Nwanguma, Advances in drug delivery systems, challenges and future directions, Heliyon, Volume 9, Issue 6, 2023, e17488,

[22] Andrea Luraghi, Francesco Peri, Lorenzo Moroni, Electrospinning for drug delivery applications: A review, Journal of Controlled Release, Volume 334,

[23] 2021, Pages 463-484, ISSN 0168-3659, https://doi.org/10.1016/j.jconrel.2021.03.033.

[24] Patra, J.K., Das, G., Fraceto, L.F. et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol 16, 71 (2018). https://doi.org/10.1186/s12951-018-0392-8

[25] Sim S, Wong NK. Nanotechnology and its use in imaging and drug delivery (Review). Biomed Rep. 2021 May;14(5):42. doi: 10.3892/br.2021.1418. Epub 2021 Mar 5. PMID: 33728048; PMCID: PMC7953199.

[26] Xuan L, Ju Z, Skonieczna M, Zhou PK, Huang R. Nanoparticles-induced potential toxicity on human health: Applications, toxicity mechanisms, and evaluation models. MedComm (2020). 2023 Jul 14;4(4):e327. doi: 10.1002/mco2.327. PMID: 37457660; PMCID: PMC10349198.

[27] Prashant Pingale, Prakash Kendre, Krutika Pardeshi, Amarjitsing Rajput,An emerging era in manufacturing of drug delivery systems: Nanofabrication techniques, Heliyon, Volume 9, Issue 3, 2023, e14247, ISSN 2405-8440 https://doi.org/10.1016/j.heliyon.2023.e14247.,An emerging era in manufacturing of drug delivery systems: Nanofabrication techniques, Heliyon, Volume 9, Issue 3, 2023, e14247, ISSN 2405-8440,https://doi.org/10.1016/j.heliyon.2023.e14247.

[28] Egwu, C.O.; Aloke, C.; Onwe, K.T.; Umoke, C.I.; Nwafor, J.; Eyo, R.A.; Chukwu, J.A.; Ufebe, G.O.; Ladokun, J.; Audu, D.T.; et al. Nanomaterials in Drug Delivery: Strengths and Opportunities in Medicine. Molecules 2024, 29, 2584. https://doi.org/10.3390/molecules29112584

[29] Yuan H, Guo H, Luan X, He M, Li F, Burnett J, Truchan N, Sun D. Albumin Nanoparticle of Paclitaxel (Abraxane) Decreases while Taxol Increases Breast Cancer Stem Cells in Treatment of Triple Negative Breast Cancer. Mol Pharm. 2020 Jul 6;17(7):2275-2286. doi: 10.1021/acs.molpharmaceut.9b01221. Epub 2020 Jun 17. PMID: 32485107; PMCID: PMC8829889

[30] M.O. Ori, F.M. Ekpan, H.S. Samuel, O.P. Egwuatu, Integration of Artificial Intelligence in Nanomedicine. Eurasian J. Sci. Technol., 2024, 4(2), 88-104.

[31] Huma Ghazal, Aimen Waqar, Faiza Yaseen, Muhammad Shahid, Mahnoor Sultana, Mehlayl Tariq, Muhammad Kamran Bashir, Hira Tahseen, Tehreem Raza, Farooq Ahmad, Role of nanoparticles in enhancing chemotherapy efficacy for cancer treatment, Next Materials, Volume 2, 2024, 100128, ISSN 2949-8228, https://doi.org/10.1016/j.nxmate.2024.100128